SCHEMBL12286133

SCHEMBL12286133

Cc1cccc(C(=O)N2CCN(CCO)CC2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.64
▸ LDHA P00338 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.56
▸ POLB P06746 1/20 0.56
▸ AKR1C3 P42330 1/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ HTT P42858 1/20 0.54
▸ GABRD O14764 1/20 0.53
▸ GABRA1 P14867 1/20 0.53
▸ GABRB1 P18505 1/20 0.53
▸ GABRA5 P31644 1/20 0.53
▸ GABRA3 P34903 1/20 0.53
▸ GABRA2 P47869 1/20 0.53
▸ GABRB2 P47870 1/20 0.53
▸ GABRA4 P48169 1/20 0.53
▸ ABL1 P00519 1/20 0.53
▸ BCR P11274 1/20 0.53
▸ MEN1 O00255 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ TSHR P16473 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7130857 0.86 HPGD (0.83) HPGDALDH1A1L3MBTL1HTTGABRD
SCHEMBL14238822 0.86 HPGD (0.83) HPGDALDH1A1L3MBTL1HTTGABRD
SCHEMBL13246374 0.85 HPGD (0.68) HPGDLDHAALDH1A1L3MBTL1HTT
SCHEMBL12835048 0.85 LDHA (0.63) HPGDLDHAL3MBTL1HTT
SCHEMBL8360507 0.83 HPGD (0.73) HPGDALDH1A1POLBL3MBTL1HTT
SCHEMBL10211716 0.82 ALDH1A1 (0.69) HPGDALDH1A1POLBAKR1C3MEN1
SCHEMBL24956770 0.82 HPGD (0.62) HPGDLDHAL3MBTL1HTTGABRD
SCHEMBL12630845 0.82 HPGD (0.62) HPGDLDHAL3MBTL1HTTGABRD
SCHEMBL1192814 0.82 KMT2A (0.71) HPGDALDH1A1POLBMEN1LMNA
SCHEMBL19634706 0.81 PARP1 (0.58) ALDH1A1POLBL3MBTL1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 — — US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 — — US disclosed
WO-2009100282-A1 FURO-AND THIENO[3,2-C] PYRIDINES OSI PHARMACEUTICALS, INC. (US) 2009-08-13 — — WO disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 — — US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines RET, MET, ERBB2 HPGD 1897/4885LDHA 3568/4885ALDH1A1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback